Key facts
- Clarametyx Biosciences’s last known valuation is $92.0M (Jul 2025).
- It has raised $44.0M across 1 recorded rounds; the latest was Early Stage VC ($27.5M) in Jan 2024.
- Notable investors include JobsOhio Ventures, Rev1 Ventures, CincyTech, CARB-X, Nationwide Children's Hospital — 8 tracked in total.
- Clarametyx Biosciences has filed 1 Form D with the SEC, most recently Jan 2024 ($27.5M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Clarametyx Biosciences
Funding rounds
1 roundsAbout Clarametyx Biosciences
Developer of immune-facilitated biologic therapies designed to fight life-threatening infections. The company's novel technology platform targets the protective barrier around bacteria through biological therapies, enabling healthcare professionals to target the challenging infections fueled by biofilms and reduce antibiotic resistance.
- Sector
- Healthcare
- HQ
- Columbus, OH, United States
- Founded
- 2019
- Employees
- 14
- Website
- clarametyx.com/
- Ownership
- Privately Held (backing)
Clarametyx Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clarametyx Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clarametyx Biosciences in its N-PORT filings yet. We sweep new filings monthly.